Literature DB >> 26681461

Glycolysis and EZH2 boost T cell weaponry against tumors.

Glenn R Bantug1, Christoph Hess1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26681461     DOI： 10.1038/ni.3346

Source DB:  PubMed          Journal:  Nat Immunol        ISSN： 1529-2908            Impact factor:   25.606


× No keyword cloud information.
  13 in total

1.  The polycomb protein Ezh2 regulates differentiation and plasticity of CD4(+) T helper type 1 and type 2 cells.

Authors:  Damon J Tumes; Atsushi Onodera; Akane Suzuki; Kenta Shinoda; Yusuke Endo; Chiaki Iwamura; Hiroyuki Hosokawa; Haruhiko Koseki; Koji Tokoyoda; Yutaka Suzuki; Shinichiro Motohashi; Toshinori Nakayama
Journal:  Immunity       Date:  2013-11-14       Impact factor: 31.745

2.  Ezh2 regulates transcriptional and posttranslational expression of T-bet and promotes Th1 cell responses mediating aplastic anemia in mice.

Authors:  Qing Tong; Shan He; Fang Xie; Kazuhiro Mochizuki; Yongnian Liu; Izumi Mochizuki; Lijun Meng; Hongxing Sun; Yanyun Zhang; Yajun Guo; Elizabeth Hexner; Yi Zhang
Journal:  J Immunol       Date:  2014-04-23       Impact factor: 5.422

3.  Rapid effector function of memory CD8+ T cells requires an immediate-early glycolytic switch.

Authors:  Patrick M Gubser; Glenn R Bantug; Leyla Razik; Marco Fischer; Sarah Dimeloe; Gideon Hoenger; Bojana Durovic; Annaïse Jauch; Christoph Hess
Journal:  Nat Immunol       Date:  2013-08-18       Impact factor: 25.606

4.  Posttranscriptional control of T cell effector function by aerobic glycolysis.

Authors:  Chih-Hao Chang; Jonathan D Curtis; Leonard B Maggi; Brandon Faubert; Alejandro V Villarino; David O'Sullivan; Stanley Ching-Cheng Huang; Gerritje J W van der Windt; Julianna Blagih; Jing Qiu; Jason D Weber; Edward J Pearce; Russell G Jones; Erika L Pearce
Journal:  Cell       Date:  2013-06-06       Impact factor: 41.582

5.  Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer.

Authors:  Eric Tran; Simon Turcotte; Alena Gros; Paul F Robbins; Yong-Chen Lu; Mark E Dudley; John R Wunderlich; Robert P Somerville; Katherine Hogan; Christian S Hinrichs; Maria R Parkhurst; James C Yang; Steven A Rosenberg
Journal:  Science       Date:  2014-05-09       Impact factor: 47.728

6.  Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression.

Authors:  Chih-Hao Chang; Jing Qiu; David O'Sullivan; Michael D Buck; Takuro Noguchi; Jonathan D Curtis; Qiongyu Chen; Mariel Gindin; Matthew M Gubin; Gerritje J W van der Windt; Elena Tonc; Robert D Schreiber; Edward J Pearce; Erika L Pearce
Journal:  Cell       Date:  2015-08-27       Impact factor: 41.582

7.  Rescue of notch-1 signaling in antigen-specific CD8+ T cells overcomes tumor-induced T-cell suppression and enhances immunotherapy in cancer.

Authors:  Rosa A Sierra; Paul Thevenot; Patrick L Raber; Yan Cui; Chris Parsons; Augusto C Ochoa; Jimena Trillo-Tinoco; Luis Del Valle; Paulo C Rodriguez
Journal:  Cancer Immunol Res       Date:  2014-05-15       Impact factor: 11.151

8.  A central role for Notch in effector CD8(+) T cell differentiation.

Authors:  Ronald A Backer; Christina Helbig; Rebecca Gentek; Andrew Kent; Brian J Laidlaw; Claudia X Dominguez; Yevan S de Souza; Stella E van Trierum; Ruud van Beek; Guus F Rimmelzwaan; Anja ten Brinke; A Marcel Willemsen; Antoine H C van Kampen; Susan M Kaech; J Magarian Blander; Klaas van Gisbergen; Derk Amsen
Journal:  Nat Immunol       Date:  2014-10-26       Impact factor: 25.606

9.  Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses.

Authors:  Ping-Chih Ho; Jessica Dauz Bihuniak; Andrew N Macintyre; Matthew Staron; Xiaojing Liu; Robert Amezquita; Yao-Chen Tsui; Guoliang Cui; Goran Micevic; Jose C Perales; Steven H Kleinstein; E Dale Abel; Karl L Insogna; Stefan Feske; Jason W Locasale; Marcus W Bosenberg; Jeffrey C Rathmell; Susan M Kaech
Journal:  Cell       Date:  2015-08-27       Impact factor: 41.582

10.  Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction.

Authors:  Ende Zhao; Tomasz Maj; Ilona Kryczek; Wei Li; Ke Wu; Lili Zhao; Shuang Wei; Joel Crespo; Shanshan Wan; Linda Vatan; Wojciech Szeliga; Irene Shao; Yin Wang; Yan Liu; Sooryanarayana Varambally; Arul M Chinnaiyan; Theodore H Welling; Victor Marquez; Jan Kotarski; Hongbo Wang; Zehua Wang; Yi Zhang; Rebecca Liu; Guobin Wang; Weiping Zou
Journal:  Nat Immunol       Date:  2015-11-02       Impact factor: 25.606
View more
  2 in total

1.  The Role of the Histone Methyltransferase Enhancer of Zeste Homolog 2 (EZH2) in the Pathobiological Mechanisms Underlying Inflammatory Bowel Disease (IBD).

Authors:  Olga F Sarmento; Phyllis A Svingen; Yuning Xiong; Zhifu Sun; Adebowale O Bamidele; Angela J Mathison; Thomas C Smyrk; Asha A Nair; Michelle M Gonzalez; Mary R Sagstetter; Saurabh Baheti; Dermot P B McGovern; Jessica J Friton; Konstantinos A Papadakis; Goel Gautam; Ramnik J Xavier; Raul A Urrutia; William A Faubion
Journal:  J Biol Chem       Date:  2016-12-01       Impact factor: 5.157

Review 2.  Structure of the PRC2 complex and application to drug discovery.

Authors:  Yi Shi; Xiao-Xi Wang; You-Wen Zhuang; Yi Jiang; Karsten Melcher; H Eric Xu
Journal:  Acta Pharmacol Sin       Date:  2017-04-17       Impact factor: 6.150
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.